UBS Group AG Decreases Stock Position in Stoke Therapeutics, Inc. $STOK
UBS Group AG significantly reduced its stake in Stoke Therapeutics (NASDAQ:STOK) by 44.5% in the fourth quarter, now holding 169,713 shares valued at $5.39 million. This adjustment follows mixed financial results from Stoke Therapeutics, which reported a narrower-than-expected quarterly loss but missed revenue forecasts. Despite this, Wall Street analysts maintain a "Moderate Buy" rating for STOK, with a consensus price target of $41.83, indicating cautious optimism for the stock's future.
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
Stoke Therapeutics (STOK) is advancing its lead candidate, zorevunersen, for Dravet syndrome, which has received Breakthrough Therapy designation from the FDA. The company's shares have significantly outperformed the industry, and it has a strategic collaboration with Biogen. With strong cash reserves and positive Zacks Rank, the article suggests Stoke Therapeutics is a good investment, also highlighting other top-ranked biotech stocks.
Stoke Therapeutics (STOK) Is Down 7.8% After Sharp Q1 Swing From Profit To Loss – What's Changed
Stoke Therapeutics (STOK) experienced a significant financial shift in Q1 2026, swinging from a net profit to a US$50 million net loss, with sales dropping to US$6.23 million. This change is primarily attributed to increased spending on its EMPEROR Phase III program and preparations for commercialization of zorevunersen, rather than a fundamental change in its pipeline prospects. Despite the short-term volatility and financial setback, the company's investment narrative remains centered on the success of its RNA platform and the upcoming regulatory milestones for its Dravet syndrome treatment.
Stoke Therapeutics (STOK) Is Down 7.8% After Sharp Q1 Swing From Profit To Loss – What's Changed
Stoke Therapeutics (STOK) experienced a significant financial shift in Q1 2026, moving from a net profit to a US$50 million net loss, with sales of US$6.23 million. This change is primarily linked to increased spending on advancing its EMPEROR Phase III program and preparing for potential commercialization of zorevunersen. Despite the near-term volatility, the company's investment narrative still hinges on the success of its RNA platform and upcoming regulatory milestones, with analysts predicting future revenue and earnings decreases but a fair value implying an upside.
Zorevunersen tied to long-term benefits in Dravet syndrome
Four-year data from long-term extension studies (SWALLOWTAIL and LONGWING) for Stoke Therapeutics' zorevunersen show sustained seizure reductions and cognitive and behavioral improvements in patients with Dravet syndrome. The investigational therapy, designed to increase functional NaV1.1 production, was generally well tolerated. Enrollment for the global Phase 3 EMPEROR trial is expected to complete in June, with data anticipated in mid-2027 to support a U.S. regulatory submission.
Lynx1 (STOK) files 13G/A reporting 4.76M shares, 8.1% stake
Lynx1 Capital Management LP and Weston Nichols have filed a Schedule 13G/A, disclosing an 8.1% beneficial ownership stake in Stoke Therapeutics (STOK), totaling 4,763,673 shares. This updated filing combines previously reported holdings with an additional 642,429 shares, indicating a significant but passive investment. The reported stake is based on 59,150,790 shares outstanding as of February 28, 2026, and grants shared voting and dispositive power to the reporting persons.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics, Inc. (Nasdaq: STOK) announced it granted stock options to eight new employees to purchase an aggregate of 106,200 shares of common stock. These grants were made effective May 15, 2026, as a material inducement for their employment under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $30.08 per share and will vest over a four-year period.
RTW Funds and R. Wong report 9.99% stake in Stoke Therapeutics (STOK)
RTW Investments, LP and Roderick Wong, M.D. have filed an amended Schedule 13G/A, reporting a shared beneficial ownership of 5,940,866 shares in Stoke Therapeutics (STOK), which represents 9.99% of the common stock. This percentage includes the assumed exercise of 317,341 warrants and is based on 59,150,790 shares outstanding as of February 28, 2026. The filing indicates a passive investment intent, with shared voting and dispositive power over the shares, and specifies that RTW Funds, including RTW Master Fund Ltd., are entitled to receive dividends or sale proceeds.
Wellington affiliates hold 3.1M shares in Stoke Therapeutics (STOK)
Wellington Management-related entities have disclosed beneficial ownership of 3,095,700 shares of Stoke Therapeutics (STOK) common stock, representing 5.23% of the class as of March 31, 2026. These shares are held for clients of Wellington investment advisers, with shared voting and dispositive power across affiliated entities. The filing is a passive ownership disclosure under Schedule 13G, indicating that clients hold the economic interest and no single client is known to hold more than 5% separately.
Redmile Group reports 4.16M shares in Stoke Therapeutics (STOK)
Redmile Group, LLC and related entities, including Jeremy C. Green and Redmile Biopharma Investments III, L.P., have reported beneficial ownership of common stock in Stoke Therapeutics, Inc. as of March 31, 2026. An amended Schedule 13G/A filing indicates that Redmile Group and Jeremy C. Green each beneficially own 4,164,120 shares (6.7% of the class), while Redmile Biopharma Investments III, L.P. holds 3,505,612 shares (5.6%). All reporting entities hold shared voting and dispositive power over their respective reported shares.
Lynx1 Capital discloses 4.12M shares of Stoke Therapeutics (STOK)
Lynx1 Capital Management and Weston Nichols have disclosed in a Schedule 13G/A filing that they beneficially own 4,121,244 shares of Stoke Therapeutics (STOK) common stock, which represents a 7.0% stake in the company. This passive investment filing indicates shared voting and dispositive power over the shares, with the Lynx1 Fund retaining rights to dividends and sale proceeds. The ownership percentage is based on 59,150,790 shares outstanding as of February 28, 2026, as reported in Stoke Therapeutics' Form 10-K.
TD Bank (NASDAQ: STOK) reports 3.18M shares, 5.4% stake
TD Bank and TD Securities Inc. have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 3,175,558 shares, or a 5.4% stake, in Stoke Therapeutics (NASDAQ: STOK) as of March 31, 2026. The filing indicates that TD Bank has sole voting and dispositive power over 3,173,258 shares, while TD Securities Inc. holds similar power over 2,300 shares. This passive investment disclosure highlights their significant, though non-controlling, interest in the biotechnology company.
Stoke Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:STOK) 2026-05-11
Stoke Therapeutics, Inc. (STOK) reported its Q1 2026 earnings, with an EPS of -$0.79, beating estimates by $0.03. The company's revenue reached $6.23M, exceeding expectations by $1.10M despite a 96.07% year-over-year decline. This information was released in conjunction with their earnings call presentation.
BTIG Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $39
BTIG has reiterated its Buy rating for Stoke Therapeutics (STOK.US), maintaining a target price of $39. This indicates a continued positive outlook on the company's stock performance by the investment firm.
Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results
Stoke Therapeutics, Inc. (NASDAQ:STOK) recently reported strong quarterly results with revenues beating estimates. Despite a projected decline in 2026 revenues, analysts have grown slightly more optimistic about shrinking losses, leading to an 8.2% increase in the consensus price target to US$45.10. However, the company's expected revenue performance is anticipated to be substantially worse than the broader biotech industry.
Stoke Therapeutics' (STOK) "Buy" Rating Reiterated at BTIG Research
BTIG Research has reiterated its "buy" rating and a $39 price target for Stoke Therapeutics (STOK), indicating an 18.6% upside. This follows the company's recent quarterly earnings, which slightly beat EPS estimates but missed revenue expectations. Analyst sentiment remains broadly positive with a "Moderate Buy" consensus, despite recent insider share sales.
Stoke Therapeutics (NasdaqGS:STOK) Stock Forecast & Analyst Predictions
Stoke Therapeutics (STOK) is predicted to grow earnings by 44.7% and revenue by 56.3% per annum, but is expected to remain unprofitable for the next three years with a forecast return on equity of -28.4% in three years. Recent updates include exceeding Q1 2026 analyst expectations for EPS and revenue, a significant net loss due to the absence of prior licensing revenue, and ongoing Phase 3 trials for zorevunersen for Dravet Syndrome with data expected mid-227. Insider selling by executives has also been noted.
STOK Reiterates by BTIG -- Price Target Maintained at $39.00
BTIG has reiterated a "Buy" rating for Stoke Therapeutics (STOK), maintaining a price target of $39.00, indicating confidence in its growth potential. Despite this positive outlook, GuruFocus data suggests STOK is significantly overvalued by 223.3% compared to its intrinsic value, with insider activity showing $3.3 million in share sales. Investors are advised to exercise caution due to the high valuation and insider selling, despite the strong financial strength of the company.
A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $38 to $60
This article provides a quick overview of analyst ratings for Stoke Therapeutics (STOK.US), noting a forecast price range of $38 to $60. It suggests that such ratings are important for investors to consider. However, the article content is missing, preventing a detailed analysis.
Stoke Therapeutics Q1 Earnings Call Highlights
Stoke Therapeutics' Q1 earnings call highlighted positive four-year extension data for its lead drug, zorevunersen, showing durable seizure reductions and improved cognition in Dravet syndrome, with a consistent safety profile. The company is on track to complete enrollment for its Phase 3 EMPEROR trial in June, aiming for a mid-2027 data readout and potential U.S. launch in late 2027 or early 2028. Stoke ended the quarter with $411 million in cash, sufficient to fund operations through the Phase 3 readout and potential launch.
Stoke Therapeutics Q1 Earnings Call Highlights
Stoke Therapeutics' Q1 earnings call highlighted positive four-year open-label extension data for its lead therapy, zorevunersen, showing durable seizure reductions and improvements in cognition and behavior for Dravet syndrome patients. The company is on track to complete enrollment for its pivotal Phase 3 EMPEROR study in June and anticipates a potential U.S. launch in late 2027 or early 2028, pending regulatory approval. With $411 million in cash, Stoke is well-funded through the Phase 3 readout and potential launch while focusing on commercial planning for the concentrated U.S. market.
Stoke Therapeutics (NASDAQ:STOK) Announces Earnings Results, Beats Estimates By $0.01 EPS
Stoke Therapeutics (NASDAQ:STOK) announced its quarterly earnings, beating EPS estimates by $0.01 with a reported loss of $0.79 per share, though revenue of $6.23 million slightly missed forecasts. The company's conference call highlighted positive four-year OLE data for zorevunersen, showing durable seizure reductions and improved Vineland-3 subdomain scores, and updated on rapid enrollment for its Phase III EMPEROR trial. Stoke Therapeutics also confirmed sufficient cash reserves of approximately $411 million to fund operations through a potential U.S. launch in late 2027 or early 2028.
Stoke Therapeutics faces earnings test after revenue miss
Stoke Therapeutics (STOK) is facing scrutiny as it prepares to report Q1 earnings after a significant revenue miss last quarter. Analysts predict a loss of $0.81 per share on $7.07 million in revenue, an improvement from Q4 but still challenging due to unpredictable collaboration income. Despite a "Strong Buy" consensus, confidence has wavered, with EPS and revenue estimates declining in recent months, making revenue visibility and clinical progress on zorevunersen key focus areas for investors.
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Stoke Therapeutics (STOK) reported a Q1 loss of $0.79 per share, slightly better than the Zacks Consensus Estimate of a $0.80 loss, and significantly topped revenue estimates with $6.23 million, beating the consensus by 18.65%. Despite underperforming the S&P 500 year-to-date, the company's stock has gained 4.9% and currently holds a Zacks Rank #3 (Hold), suggesting a market-perform outlook. Investors will be watching management's commentary and future earnings estimates.
Stoke Therapeutics (Nasdaq: STOK) Q1 2026 loss, zorevunersen data and cash runway to 2028
Stoke Therapeutics reported a net loss of $50.0 million in Q1 2026, primarily due to the absence of a large Biogen license revenue earned in the prior year, with revenue normalizing to $6.2 million. Despite the loss, the company provided positive updates on its zorevunersen program for Dravet syndrome, including durable seizure reductions and cognitive improvements, and announced that its $411.0 million cash reserves are expected to fund operations into 2028. Stoke is also advancing its Phase 3 EMPEROR study for zorevunersen, with full enrollment anticipated by June 2026 and a planned U.S. NDA submission starting in early 2027.
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
Stoke Therapeutics announced its first-quarter 2026 financial results and provided business updates, highlighting new 4-year longitudinal data from Phase 1/2a open-label extension studies for zorevunersen, an investigational medicine for Dravet syndrome. The data showed statistically significant improvements in cognition and behavior, alongside durable seizure reductions with zorevunersen, which was generally well tolerated. The company expects to complete enrollment for its Phase 3 EMPEROR study in June 2026, with a data readout in mid-2027, and reported $411.0 million in cash, cash equivalents, and marketable securities, projected to fund operations into 2028.
Earnings Flash (STOK) Stoke Therapeutics, Inc. Reports Q1 Revenue $6.2M, vs. FactSet Est of $6.5M
Stoke Therapeutics, Inc. (STOK) reported Q1 revenue of $6.2 million, falling short of FactSet's estimate of $6.5 million. The biotechnology company focuses on developing RNA-based medicines to upregulate protein expression for severe diseases, with zorevunersen (STK-002) in clinical testing for Dravet syndrome and autosomal dominant optic atrophy. The article also highlights recent company news, including earnings calls, inducement grants, and insider stock transactions.
Stoke Therapeutics faces earnings test after revenue miss By Investing.com
Stoke Therapeutics Inc. is preparing to report its first-quarter results, facing investor scrutiny after a significant revenue shortfall last quarter. Analysts are bullish on the stock with a "Strong Buy" consensus, despite recent declines in EPS and revenue estimates. Investors will be closely watching revenue trajectory, clinical progress for its lead drug zorevunersen, and cash burn.
Stoke Therapeutics (STOK) CMO sells 2,243 shares in open-market trade
Stoke Therapeutics' Chief Medical Officer, Barry Ticho, sold 2,243 common stock shares at $32.79 each on May 1, 2026, as part of a pre-arranged Rule 10b5-1 trading plan. Following this transaction, Ticho directly holds 36,621 shares. This open-market sale is detailed in a Form 4 SEC filing, providing transparency on insider trading activity.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics (STOK) has announced inducement grants in accordance with Nasdaq Listing Rule 5635(C)(4). This information was disseminated via Quantisnow, a platform providing real-time market data and news for investors. The article also provides recent analyst ratings for Stoke Therapeutics.
Hussman Strategic Advisors Inc. Takes Position in Stoke Therapeutics, Inc. $STOK
Hussman Strategic Advisors Inc. has acquired a new stake of 63,000 shares, valued at $2 million, in Stoke Therapeutics (NASDAQ:STOK) during the fourth quarter, representing 0.11% of the company. Analysts maintain a "Moderate Buy" rating for STOK with an average target price of $41.83, despite recent insider selling totaling 69,699 shares ($2.53 million) over the last 90 days. The company reported a Q1 loss of ($0.97) EPS and currently trades around $33 with a market cap of $2.06 billion.
Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Thursday
Stoke Therapeutics (STOK) is anticipated to release its Q1 2026 earnings before market open on Thursday, May 7th, with analysts predicting a loss of ($0.80) per share and revenue of approximately $6.48 million. This follows a previous quarter where the company reported a ($0.97) EPS on $1.4 million revenue, and continued losses are projected for the current and next fiscal years. Despite recent insider stock sales totaling $2.53 million, the Street maintains a "Moderate Buy" consensus with an average price target of $41.83.
A Look At Stoke Therapeutics (STOK) Valuation After Strong 1 Year Shareholder Returns
Stoke Therapeutics (STOK) has shown strong shareholder returns over the past year, with its stock price at $33.08. Analysts consider STOK to be 3.4% undervalued, with a fair value estimate of $34.25, based on a model that projects sharp revenue resets, rich profit margins, and premium earnings multiples. However, the valuation depends heavily on the success and timely execution of Phase 3 data for zorevunersen and navigating the complexities of late-stage neurology trials.
Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome (STOK)
Stoke Therapeutics (STOK) has been initiated with a Buy rating due to the late-stage progress of its drug, zorevunersen, for SCN1A Dravet Syndrome. The phase 3 EMPEROR trial's data is expected mid-2027, with a rolling NDA submission planned for the first half of 2027. Three-year open-label data indicates zorevunersen's potential for durable seizure reduction and functional improvement, suggesting it could be a disease-modifying treatment.
Baruch S. Ticho sells STOK shares under 10b5-1 (STOK)
Baruch S. Ticho, associated with Stoke Therapeutics, Inc. (STOK), has sold shares under a 10b5-1 plan, as reported in a Form 144 SEC filing by Morgan Stanley Smith Barney LLC. The filing details multiple sales transactions occurring on March 17, 18, 19, and April 1, 2026, for a total of 16,149 shares with corresponding proceeds. These planned sales were executed under a pre-arranged trading plan, meant to avoid accusations of insider trading.
Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates
Stoke Therapeutics (Nasdaq: STOK) announced it will host a webcast and conference call on Thursday, May 7, 2026, at 4:30 p.m. ET, to provide first quarter 2026 business and financial updates. The event will be accessible via their investor website, with registration details provided for analysts participating in the Q&A. Stoke Therapeutics is a biotechnology company focused on RNA medicine with its lead investigational medicine, zorevunersen, in development for Dravet syndrome.
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of "Moderate Buy" by Brokerages
Stoke Therapeutics (NASDAQ:STOK) has received an average "Moderate Buy" rating from twelve brokerages, with a consensus 12-month target price of $41.83. The company, a clinical-stage biopharmaceutical firm focusing on rare neuromuscular and neurological disorders, recently reported a quarterly EPS of ($0.97) on $1.4 million revenue. Insider selling has been noted, with significant share sales by the General Counsel and a Director.
Is It Time To Reassess Stoke Therapeutics (STOK) After A 277% One Year Rally?
Stoke Therapeutics (STOK) has seen a significant 277% rally over the past year. Despite this, Discounted Cash Flow and Price vs. Sales analyses by Simply Wall St suggest the stock may still be undervalued. The article presents both bullish and bearish narratives for the company, with fair value estimates ranging from US$34.25 to US$39.00 per share, indicating a mixed outlook for its current price of US$35.90.
[ARS] Stoke Therapeutics, Inc. SEC Filing
This article reports on Stoke Therapeutics, Inc.'s ARS filing with the SEC, dated April 22, 2026, at 04:12 PM. The filing is available as a PDF and has a low impact and neutral sentiment. The article also provides a company overview, including market cap, float, industry, and recent news and SEC filings for STOK.
Executive pay, board elections and new auditor at Stoke Therapeutics (NASDAQ: STOK)
Stoke Therapeutics (NASDAQ: STOK) will hold its 2026 Annual Meeting of Stockholders virtually on June 3, 2026. Shareholders will vote on the election of three Class I directors, the ratification of Ernst & Young LLP as the new independent public accounting firm, and an advisory vote on named executive officer compensation. The proxy statement details executive compensation, including total compensation for the CEO ($27,031,655 in 2025) and CFO ($1,830,375 in 2025), and outlines board independence, committee structures, and the rationale behind executive long-term incentive awards, which include stock options and restricted stock units.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics announced that it granted stock options to fourteen new employees on April 15, 2026, as a material inducement for their employment under Nasdaq Listing Rule 5635(c)(4). The options, totaling 129,565 shares with an exercise price of $35.54 per share, will vest over a four-year period. Stoke Therapeutics is a biotechnology company focused on restoring protein expression using RNA medicine, with its lead investigational medicine, zorevunersen, in development for Dravet syndrome.
Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $40
Needham has reaffirmed its Buy rating on Stoke Therapeutics (STOK.US) and maintained its price target of $40. This indicates the firm's continued confidence in the company's stock performance.
Stoke Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4)
Stoke Therapeutics (STOK) has announced inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). The company specializes in developing RNA-based medicines to upregulate protein expression for severe diseases, with its primary focus on Dravet syndrome and autosomal dominant optic atrophy. The article also provides recent news and financial data related to Stoke Therapeutics.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics, Inc. (Nasdaq: STOK) announced that it granted stock options to fourteen new employees on April 15, 2026, to purchase an aggregate of 129,565 shares of common stock. These grants serve as a material inducement for their employment under Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $35.54 per share and will vest over a four-year period.
Did Stoke's New R&D Chair Appointment Just Reshape Stoke Therapeutics' (STOK) Antisense Strategy Priorities?
Stoke Therapeutics recently appointed G. Clare Kahn, Ph.D., a veteran with extensive regulatory and R&D experience, as a Class I director and chair of its Research and Development Committee. This appointment is expected to significantly influence Stoke's antisense pipeline strategy for severe genetic diseases, particularly as the company prepares for critical regulatory milestones for its lead candidate, zorevunersen, in Dravet syndrome. While not changing near-term scientific risks, Dr. Kahn's expertise could reshape how these risks are managed and impact the company's long-term investment narrative, especially concerning its approach to rare, high-priced indications.
STOK: Zorevunersen shows sustained efficacy and cognitive gains, with phase III readout expected mid-2027
Stoke Therapeutics' (STOK) Zorevunersen has demonstrated sustained efficacy and cognitive improvements in Dravet syndrome, alongside strong long-term safety data. The company plans to complete phase III trials by Q2 2026, with regulatory approval anticipated in late 2027. This positive data and a broad market opportunity underpin the commercial strategy for Zorevunersen.
Baillie Gifford & Co. Purchases New Position in Stoke Therapeutics, Inc. $STOK
Baillie Gifford & Co. has acquired a new stake in Stoke Therapeutics (NASDAQ:STOK), purchasing 246,900 shares valued at approximately $7.84 million. This move establishes Baillie Gifford & Co. as holding about 0.43% of the company's stock. Analysts generally rate STOK as a "Moderate Buy" with an average price target of $41.83, despite recent insider selling activities.
Did Stoke’s New R&D Chair Signal a Tighter Late-Stage Focus for STOK’s Pipeline Strategy?
Stoke Therapeutics appointed G. Clare Kahn, Ph.D., as chair of its R&D Committee, signaling a reinforced focus on late-stage pipeline execution, especially for its Phase 3 zorevunersen trial. Kahn brings significant regulatory and drug development experience which could impact how Stoke manages trial complexity and FDA feedback. While this strengthens the execution narrative, investors should be aware of the risk that regulators might not grant an accelerated approval.
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Stoke Therapeutics, a biotechnology company focused on RNA medicine, announced that its CEO, Ian F. Smith, will present at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, at 3:00 p.m. ET. The company's lead investigational medicine, zorevunersen, is being developed as a potential disease-modifying treatment for Dravet syndrome. A live webcast of the presentation will be available on the Investors & News section of Stoke’s website.
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
Biogen and Stoke Therapeutics will present new clinical data for zorevunersen, an investigational treatment for Dravet syndrome, at the 36th International Epilepsy Congress. The data from open-label extension studies show durable seizure reductions and improvements in cognition and behavior over three years, supporting its potential as a disease-modifying therapy. Zorevunersen is currently in a global pivotal Phase 3 study (EMPEROR) to further evaluate its efficacy, safety, and tolerability in children with Dravet syndrome.
